Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Novo Nordisk and Eli Lilly face soaring demand--and stiff competition--as obesity drug market transforms healthcare and ...

Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental ...

The latest health news includes WuXi's sale of its Advanced Therapies unit due to US restrictions, expanding famine in Sudan ...

Steve Davis, que trabalha para Elon Musk, passou mais de 20 anos ajudando o bilionário a reduzir custos em empresas como a ...

Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight loss drugs.

Healthcare stocks have gotten crushed in 2024, and next year doesn’t look much better. But there are still opportunities for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...